Back to search
FDAFDA · Food and drugs·Recall number D-1021-2018

Valsartan/HCTZ 320mg/12.5 mg tablet, 90-count bottle, Rx only, RemedyRepack, 625 Kolter Drive, Suite 4, Indiana, PA 15701

Published August 8, 2018 · Recall initiated: July 17, 2018

Summary

FDA records drug Class II recall D-1021-2018, published August 8, 2018 and initiated July 17, 2018. Recalling firm: RemedyRepack Inc.; Status: Terminated; Reported quantity: 3 HDPE 90-count bottles (270 tablets); Lot: Lot # B0383153-122917; Exp. 12/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRepack Inc.
Distributor
Product was distributed to 3 medical facilities in Florida.
Lot
Lot # B0383153-122917; Exp. 12/18
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Valsartan/HCTZ 320mg/12.5 mg tablet, 90-count bottle, Rx only, RemedyRepack, 625 Kolter Drive, Suite 4, Indiana, PA 15701 recalled?

Yes. FDA published recall D-1021-2018 on August 8, 2018. Reported hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter